Premium
Narciclasine exerts anti‐inflammatory actions by blocking leukocyte–endothelial cell interactions and down‐regulation of the endothelial TNF receptor 1
Author(s) -
Stark Anna,
Schwenk Rebecca,
Wack Gesine,
Zuchtriegel Gabriele,
Hatemler Melissa G.,
Bräutigam Jacqueline,
Schmidtko Achim,
Reichel Christoph A.,
Bischoff Iris,
Fürst Robert
Publication year - 2019
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.201802440r
Subject(s) - chemistry , proinflammatory cytokine , cell adhesion molecule , microbiology and biotechnology , nf κb , iκbα , tumor necrosis factor alpha , receptor , inflammation , signal transduction , endothelial stem cell , pharmacology , biochemistry , biology , immunology , in vitro
The alkaloid narciclasine has been characterized extensively as an anticancer compound. Accumulating evidence suggests that narciclasine has anti‐inflammatory potential; however, the underlying mechanism remains poorly understood. We hypothesized that narciclasine affects the activation of endothelial cells (ECs), a hallmark of inflammatory processes, which is a prerequisite for leukocyte‐EC interaction. Thus, we aimed to investigate narciclasine's action on this process in vivo and to analyze the underlying mechanisms in vitro . In a murine peritonitis model, narciclasine reduced leukocyte infiltration, proinflammatory cytokine expression, and inflammation‐associated abdominal pain. Moreover, narciclasine decreased rolling and blocked adhesion and transmigration of leukocytes in vivo . In cultured ECs, narciclasine inhibited the expression of cell adhesion molecules intercellular adhesion molecule‐1, vascular cell adhesion molecule‐1, and E‐selectin and blocked crucial steps of the NF‐κB activation cascade: NF‐κB promotor activity, p65 nuclear translocation, inhibitor of κB α (IκBα*) phosphorylation and degradation, and IκBα* kinase β and TGF‐β–activated kinase 1 phosphorylation. Interestingly, these effects were based on the narciclasine‐triggered loss of TNF receptor 1 (TNFR1). Our study highlights narciclasine as an interesting anti‐inflammatory compound that effectively inhibits the interaction of leukocytes with ECs by blocking endothelial activation processes. Most importantly, we showed that the observed inhibitory action of narciclasine on TNF‐triggered signaling pathways is based on the loss of TNFR1.—Stark, A., Schwenk, R., Wack, G., Zuchtriegel, G., Hatemler, M. G., Bräutigam, J., Schmidtko, A., Reichel, C. A., Bischoff, I., Fürst, R. Narciclasine exerts antiinflammatory actions by blocking leukocyte–endothelial cell interactions and down‐regulation of the endothelial TNF receptor 1. FASEB J. 33, 8771–8781 (2019). www.fasebj.org